Sign in

    Reena

    Research Analyst at Citigroup Inc.

    No comprehensive LinkedIn or publicly available data could be identified tying a Citigroup Inc. analyst named Reena to a specific analyst role, coverage list, or credential set. Without a valid LinkedIn profile and with no results listing specific job title, sector focus, company coverage, performance metrics, or licensure, a professional summary cannot be provided at this time.

    Reena's questions to Travere Therapeutics (TVTX) leadership

    Reena's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    Reena, on for Yigal Nochomovitz at Citigroup Inc., asked for commentary on FILSPARI's compliance and adherence metrics under the monthly REMS monitoring and how these might change with a reduction in monitoring frequency.

    Answer

    Chief Commercial Officer Peter Heerma stated that compliance and persistency rates are 'really high,' which he attributed to patients experiencing positive results and reaching treatment targets. President and CEO Dr. Eric Dube added that if monitoring frequency is reduced, the company would ensure patients continue to receive the right level of support and engagement.

    Ask Fintool Equity Research AI